Core Viewpoint - Fosun Pharma's subsidiary, Hanhui, received FDA approval for its self-developed denosumab injection (HLX14) in two specifications, which includes five indications for osteoporosis treatment [1] Group 1: Product Approval - The FDA approved the biologics license application (BLA) for denosumab injection in two concentrations: 60mg/mL and 120mg/1.7mL [1] - The approved indications include treatment for osteoporosis in postmenopausal women, osteoporosis in male patients, glucocorticoid-induced osteoporosis, non-metastatic prostate cancer in male patients undergoing androgen deprivation therapy, and breast cancer in women receiving aromatase inhibitor therapy [1] Group 2: Market Potential - The global sales revenue for denosumab injection is approximately $7.462 billion [1]

Group 1 - The company announced the reappointment of several members to its board committees, effective from August 29, 2025 [2] - Su Deyang was reappointed as the chairman of the Audit Committee, while Wenjie Zhang was reappointed as the chairman of the Nomination Committee [2] - The company also reappointed Chen Yuqing and Song Ruilin to the Compensation Committee, with Song Ruilin serving as the chairman [2] Group 2 - Wenjie Zhang was reappointed as the chairman of the fourth board, effective from August 29, 2025, until the term of the fourth board expires [3] - Feng Rongli was reappointed as the chairman of the fourth Supervisory Committee, effective from August 29, 2025, until the term of the fourth Supervisory Committee expires [3] - Zhu Jun was reappointed as the CEO of the company, effective from August 29, 2025, until the term of the fourth board expires [3]

Core Insights - The excitement for the company lies not in new sectors but in accelerating growth and achieving a leading position in existing sectors [1] - The company reported total revenue of 87.28 billion yuan and a net profit of 660 million yuan for the first half of 2025 [1] - The four core subsidiaries contributed 63.61 billion yuan, accounting for 73% of total revenue [1] Innovation and R&D - The company invested 3.6 billion yuan in its innovation sector during the reporting period [2] - The pharmaceutical segment is both an established industry and a driver of innovation, with multiple new drug approvals and submissions [2] - The company has a robust pipeline of innovative products with significant global market potential [2] Global Expansion - Overseas revenue reached 46.67 billion yuan, making up 53% of total revenue [4] - The company has made significant strides in global business, with overseas product profits increasing over 200% and cash inflow from business development contracts rising by 280% [4] - The company is expanding its presence in various international markets, including the Middle East and Southeast Asia [4] Financial Health - The company is executing a "slimming down" strategy, with over 8 billion yuan returned from asset exits and subsidiary dividends [6] - Total debt as a percentage of total capital stands at 53%, indicating a reasonable debt ratio [7] - The company is focused on reducing financial costs and has seen a slight decrease in interest-bearing debt [7] Strategic Vision - The company aims to enhance its global R&D, business development, and operational capabilities to become a leading global pharmaceutical enterprise [3][5] - The strategy includes a focus on "innovation + globalization" to maximize the value of its innovative products [3] - The company is committed to deepening its core business and accelerating innovation while pursuing global development [7]

Group 1: Company Performance - Renfu Pharmaceutical reported a 6.2% decline in revenue to 12.064 billion yuan, while net profit increased by 3.92% to 1.155 billion yuan [1] - Junshi Biosciences achieved a 48.64% increase in revenue to 1.168 billion yuan, with a net loss of 413 million yuan [2] - Fuhong Hanlin's revenue for the first half of 2025 was 2.8195 billion yuan, a 2.7% year-on-year increase, with a net profit of 390.1 million yuan [6] Group 2: Market Position and Product Development - Renfu Pharmaceutical holds over 60% market share in the domestic anesthetic drug market, with its subsidiary Yichang Renfu being the largest R&D and production base in Asia [1] - Junshi Biosciences' core product, Toripalimab, generated sales revenue of approximately 1.059 billion yuan, a 49.41% increase, with domestic sales reaching about 954 million yuan, up 42% [2] - Beijing Kexing's adsorbed tetanus vaccine received drug registration approval, enhancing the company's portfolio in the trauma field [3] Group 3: Strategic Partnerships and Financial Transactions - BeiGene signed a royalty transfer agreement with Royalty Pharma for Tarlatamab, potentially worth up to 950 million USD, with an initial payment of 885 million USD [4] - Lepu Medical's management expressed a desire to avoid selling potential products at low prices early in the development process, indicating a focus on maintaining financial strength [5][6] - Fuhong Hanlin reported over 1 billion yuan in cash inflow from BD contracts, with a significant increase in overseas product profits [6]

Group 1 - The company, Fuhong Hanlin (02696.HK), announced on August 29, 2023, that the board of directors resolved to grant a total of 67,500 stock options to 4 participants under the stock option plan [1] - Additionally, the company will grant a total of 87,500 restricted stock units to 8 participants under the restricted stock unit plan [1]

Group 1 - The company, Fuhong Hanlin (02696), announced that on August 29, 2025, the board of directors resolved to grant a total of 67,500 stock options to 4 participants under the stock option plan [1] - Additionally, the company will grant a total of 8,750 restricted stock units to 8 participants under the restricted stock unit plan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 授出購股權及受限制股份單位 A. 緒言 本公告乃根據上市規則第17.06A、17.06B及17.06C條作出。 於2025年8月29日，董事會決議根據購股權計劃向4名參與者授出合共67,500份購 股權及根據受限制股份單位計劃向8名參與者授出合共87,500份受限制股份單位。 B. 根據購股權計劃授出購股權 於2025年8月29日，董事會決議根據購股權計劃向4名參與者授出合共67,500份購 股權。授出購股權的條款如下： 授予日 ： 2025年8月29日 (iii) H股的面值人民幣1.00元。 1 承授人類別及授出的 購股權數目 ： 4 名僱員參與者（不包括董事）：合共67,500 份 購股權（代表可認購67,500股H股的權利，佔本 公告日 ...

Core Points - The company has announced the reappointment of several members to its board committees, effective from August 29, 2025 [1] - Wenjie Zhang has been reappointed as the chairman of the board, with his term starting on August 29, 2025, until the end of the fourth board term [2] - Zhu Jun has been reappointed as the CEO, effective from August 29, 2025, and will continue to lead the management team [2] Board Committees Summary - Su Deyang, Chen Liyuan, and Guan Xiaohui have been reappointed as members of the Audit Committee, with Su Deyang serving as the chairman [1] - Yihao Zhang has been appointed, and Wenjie Zhang, Guan Xiaohui, Su Deyang, and Song Ruilin have been reappointed to the Nomination Committee, with Wenjie Zhang as the chairman [1] - Chen Yuqing has been appointed, and Song Ruilin and Chen Liyuan have been reappointed to the Compensation Committee, with Song Ruilin as the chairman [1] - Chen Yuqing and Liu Yi have been appointed, and Wenjie Zhang, Zhu Jun, Chen Qiyu, Xingli Wang, Su Deyang, and Song Ruilin have been reappointed to the Strategy Committee, with Wenjie Zhang as the chairman [1] - Chen Liyuan, Su Deyang, Song Ruilin, Wenjie Zhang, and Zhu Jun have been reappointed to the Environmental, Social, and Governance Committee, with Chen Liyuan as the chairman [1] - Wu Yifang, Wen Deyong, and Zhao Guoping have retired from their positions as non-executive and independent non-executive directors and will no longer serve on the relevant board committees [1]

上海復宏漢霖生物技術股份有限公司 經修訂及重列之章程 （經公司於2025年8月29日舉行的股東會審議通過） | 目錄 | | --- | | 第一章 | 總則 | | 1 | | --- | --- | --- | --- | | 第二章 | | 經營宗旨和範圍 | 4 | | 第三章 | 股份 | | 4 | | 第一節 | | 股份發行 | 4 | | 第二節 | 股份增減和回購 | | 5 | | 第三節 | | 股份轉讓 | 6 | | 第四節 | | 購買公司股份的財務資助 | 7 | | 第四章 | | 股東和股東會 | 7 | | 第一節 | 股東和股東名冊 | | 7 | | 第二節 | 股東會的一般規定 | | 12 | | 第三節 | | 股東會的召集 | 13 | | 第四節 | | 股東會的提案與通知 | 14 | | 第五節 | | 股東會的召開 | 15 | | 第六節 | | 股東會的表決和決議 | 18 | | 第五章 | 董事會 | | 20 | | 第一節 | | 董事 | 20 | | 第二節 | 獨立非執行董事 | | 21 | | 第三節 | | 董事會 | 21 | ...

董事名單與其角色及職能 董事名單與其角色及職能 董事會（「董事會」）成員載列如下： 董事會主席 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 相關董事會委員會成員載列如下： | | | | | | 環境、社會 及 | | --- | --- | --- | --- | --- | --- | | 董事 | 審計委員會 | 薪酬委員會 | 提名委員會 | 戰略委員會 | 管治委員會 | | Wenjie Zhang先生 | | | C | C | M | | 朱俊博士 | | | | M | M | | 陳啟宇先生 | | | | M | | | 陳玉卿先生 | | M | | M | | | 關曉暉女士 | M | | M | | | | 劉毅博士 | | | | M | | | Xing ...